Cancer　immunotherapy　is　an　attractive　strategy　because　it　stimulates　immune　cells　to　target　malignant　cells　by　regulating　the　intrinsic　activity　of　the　immune　system.　However,　due　to　lacking　many　immunologic　markers,　it　remains　difficult　to　treat　glioma,　a　representative　＇cold＇　tumor.　Herein,　to　wake　the　＇hot＇　tumor　immunity　of　glioma,　Porphyromonas　gingivalis　(Pg)　is　customized　with　a　coating　to　create　an　immunogenic　tumor　microenvironment　and　further　prove　the　effect　in　combination　with　the　immune　checkpoint　agent　anti-PD-1,　exhibiting　elevated　therapeutic　efficacy.　This　is　accomplished　not　by　enhancing　the　delivery　of　PD-1　blockade　to　enhance　the　effect　of　immunotherapy,　but　by　introducing　bacterial　photothermal　therapy　to　promote　greater　involvement　of　M1　cells　in　the　immune　response.　After　reaching　glioma,　the　bacteria　further　target　glioma　cells　and　M2　phenotype　macrophages　selectively,　enabling　precise　photothermal　conversion　for　lysing　tumor　cells　and　M2　phenotype　macrophages,　which　thereby　enhances　the　positive　feedback　loop　of　cancer　cells-M1　macrophages-T　cells.　Collectively,　the　bacteria　synergized　with　PD-1　blockade　strategy　may　be　the　key　to　overcoming　the　immunosuppressive　glioma　microenvironment　and　improving　the　outcome　of　immunotherapy　toward　glioma.　©　2024　The　Authors.　Advanced　Science　published　by　Wiley-VCH　GmbH.